Database Query Results : , , IL1α
IL1α, interleukin-1 alpha: Click to Expand ⟱
| Source: |
| Type: |
The term "IL-1" is often used as an umbrella term for the interleukin-1 family, which includes multiple cytokines. The two best-known members are IL-1α and IL-1β.
L-1α: Often expressed as a precursor that is biologically active even before processing; it can be active in its intracellular form and when expressed on the cell surface.
IL-1α is typically associated with cell damage and tends to act more locally.
High IL-1α levels have been detected in a number of tumor cells and have been associated with enhanced tumor invasion and metastasis in several settings.
|
Scientific Papers found: Click to Expand⟱
TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,
*Inflam↓, AntiCan↑, *MAPK↑, *Ca+2↝, p‑ERK↓, TumCI↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, *NF-kB↓, *TNF-α↓, NF-kB↓, IKKα↓, MCP1↓, IL1α↓, MIP2↓, VEGF↓, Tf↓, COX2↓, MMP9↓, CXCR4↓, VEGF↓, eff↑, PPARα↓, lipid-P?, STAT3↓, TOP1↓, TOP2↑, 5HT↓, p‑PDGFR-BB↓, PDGF↓, AR↓, DR5↑, angioG↓, DR4↑, Casp3↑, Casp8↑, cl‑PARP↑, eff↑, chemoPv↑, Wnt↓, β-catenin/ZEB1↓, ascitic↓, Let-7↑, miR-200b↑, eff↑, MMP1↓, MMP2↓, eff↑, BioAv↓, BioAv↑, Half-Life↓, toxicity↓, Dose↑, BioAv↑, ChemoSen↑,
*antiOx↑, *Inflam↓, *ROS↓, *IL1α↓, *AhR↑, *NRF2↑, *IL8↓,
*toxicity∅, *Dose↝, *Dose↝, *BioAv↝, *BioAv↝, *H2O2∅, *IL8∅, *IL1α∅, *IL1β∅, *MCP1∅, *NQO1∅, *BioAv↓,
IL1α↓, other↝,
*memory↑, *Aβ↓, *toxicity↓, *BBB↑, *p‑tau↓, *eff↓, *IL1α↓, *MCP1↓, *MIP‑1α↓, *TNF-α↓, *IL2↓, *SIRT1↓, *DNAdam↓, *Dose↝, *Strength↑, *motorD↑, *CTSZ↓,
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned ⓘ
chemoPv↑, 1,
Redox & Oxidative Stress ⓘ
lipid-P?, 1,
Metal & Cofactor Biology ⓘ
Tf↓, 1,
Core Metabolism/Glycolysis ⓘ
PPARα↓, 1, p‑S6↓, 1,
Cell Death ⓘ
Akt↓, 1, p‑Akt↓, 1, Apoptosis↑, 1, BAX↑, 1, Bcl-2↓, 1, Bcl-xL↓, 1, Casp3↑, 1, Casp8↑, 1, DR4↑, 1, DR5↑, 1,
Transcription & Epigenetics ⓘ
other↝, 1,
DNA Damage & Repair ⓘ
DNAdam↑, 1, P53↑, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence ⓘ
CDK1↓, 1, CDK2↓, 1, CDK4↓, 1, cycA1/CCNA1↓, 1, CycB/CCNB1↓, 1, cycD1/CCND1↓, 1, cycE/CCNE↓, 1, p‑RB1↓, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
ERK↓, 1, p‑ERK↓, 2, Let-7↑, 1, mTOR↓, 1, p‑P70S6K↓, 1, p‑P90RSK↑, 1, PI3K↓, 1, STAT3↓, 2, TOP1↓, 1, TOP2↑, 1, Wnt↓, 1, Wnt/(β-catenin)↓, 1,
Migration ⓘ
miR-200b↑, 1, MMP1↓, 1, MMP2↓, 2, MMP9↓, 2, PDGF↓, 1, TumCI↓, 2, TumCMig↓, 1, TumCP↓, 1, β-catenin/ZEB1↓, 1,
Angiogenesis & Vasculature ⓘ
angioG↓, 1, Hif1a↓, 1, p‑PDGFR-BB↓, 1, VEGF↓, 3,
Immune & Inflammatory Signaling ⓘ
COX2↓, 1, CXCR4↓, 1, IKKα↓, 2, IL1α↓, 3, IL6↓, 1, MCP1↓, 1, MIP2↓, 1, NF-kB↓, 1, TNF-α↓, 1,
Synaptic & Neurotransmission ⓘ
5HT↓, 1,
Hormonal & Nuclear Receptors ⓘ
AR↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 1, BioAv↑, 2, ChemoSen↑, 1, Dose↑, 1, eff↑, 4, Half-Life↓, 1,
Clinical Biomarkers ⓘ
AR↓, 1, ascitic↓, 1, IL6↓, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, toxicity↓, 1,
Total Targets: 75
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
antiOx↑, 1, H2O2∅, 1, NQO1∅, 1, NRF2↑, 1, ROS↓, 1,
Core Metabolism/Glycolysis ⓘ
SIRT1↓, 1,
Cell Death ⓘ
AhR↑, 1, MAPK↑, 1,
DNA Damage & Repair ⓘ
DNAdam↓, 1,
Migration ⓘ
Ca+2↝, 1,
Barriers & Transport ⓘ
BBB↑, 1,
Immune & Inflammatory Signaling ⓘ
CTSZ↓, 1, IL1α↓, 2, IL1α∅, 1, IL1β∅, 1, IL2↓, 1, IL8↓, 1, IL8∅, 1, Inflam↓, 2, MCP1↓, 1, MCP1∅, 1, MIP‑1α↓, 1, NF-kB↓, 1, TNF-α↓, 2,
Synaptic & Neurotransmission ⓘ
p‑tau↓, 1,
Protein Aggregation ⓘ
Aβ↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↓, 1, BioAv↝, 2, Dose↝, 3, eff↓, 1,
Functional Outcomes ⓘ
memory↑, 1, motorD↑, 1, Strength↑, 1, toxicity↓, 1, toxicity∅, 1,
Total Targets: 35
Scientific Paper Hit Count for: IL1α, interleukin-1 alpha
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:977 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid
Home Page